Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?

To: richardred who wrote (792)	7/5/2005 6:55:07 PM
From: richardred	Respond to of 7265

West to Buy Medimop for More Than $40M Tuesday July 5, 6:25 pm ET West Pharmaceuticals Agrees to Acquire Medimop Medical Projects for More Than $40 Million LIONVILLE, Pa. (AP) -- West Pharmaceuticals Inc., a maker of syringe parts, on Tuesday said it has agreed to acquire Israel-based Medimop Medical Projects Ltd., a manufacturer of devices for injectable drugs. Under the deal, West will purchase 90 percent of Medimop's outstanding shares for $36 million cash, $4 million in stock and up to $1.8 million cash in additional contingency fees. Although Medimop founder and President Freddy Zinger retains the remaining 10 percent stake, West will have the option to buy his shares in the future. West said it will finance the purchase with bank debt and planned private lender debt. The company said the acquisition will not effect earnings in 2005 on sales of $8 million for the year. The transaction is expected to close in the third quarter. Medimop managers will remain at the company's Ra'anana, Israel, headquarters. The company has about 20 employees and manufactures its products in Israel and Germany. Shares of West Pharmaceuticals closed 50 cents higher to $28.60 on the New York Stock Exchange. biz.yahoo.com

To: richardred who wrote (792)	7/6/2005 9:52:53 AM
From: richardred	Respond to of 7265

Neogen to Acquire UCB's Dairy Antibiotic Testing Business Wednesday July 6, 9:06 am ET LANSING, Mich., July 6 /PRNewswire-FirstCall/ -- Neogen Corporation (Nasdaq: NEOG - News) today announced it has signed an agreement with Brussels, Belgium-based UCB (Euronext Brussels) to acquire UCB's dairy antibiotic testing business. Closing is expected to take place late in the 2005 calendar year. UCB's dairy antibiotic testing products present a strong complementary fit with other testing products that Neogen offers the dairy industry, including an ATP sanitation monitoring system, water quality test, food allergen tests, and bacteria tests. Considerations for the acquisition include $14.7 million (U.S.) in cash, and potential future performance-based compensation. "Dairy antibiotic testing products have been on our radar screen for many years because of their synergistic fit to our business," said James Herbert, Neogen's President. "This transaction comes at a time and price that makes good sense for both of our companies. We look forward to adding UCB's exceptional antibiotic tests to our product line, and introducing UCB's customer base to our comprehensive group of products." Sales of UCB's dairy testing products approximated $9 million (U.S.) in its most recent fiscal year, of which over 90% represented sales outside North America. Beta Star, one of UCB's key dairy antibiotic testing products, does not yet have FDA approval for sale to the large dairy market in the United States, but that approval is being pursued. Milk processors typically test raw milk arriving from dairy farms for antibiotic residues. Products involved in the acquisition include the widely-used Penzyme product, and the newer technology Beta Star test. The Beta Star test uses a format nearly identical to Neogen's simple dipstick tests for mycotoxins, food allergens, and ruminant by-products. About UCB: UCB - ucb-group.com - is a global biopharmaceutical leader with headquarters in Brussels, Belgium, specializing in the fields of central nervous system disorders, allergy and respiratory diseases, immune and inflammatory disorders, as well as oncology. UCB key products are Keppra® (antiepileptic), Xyzal® and Zyrtec® (antiallergics), Nootropil® (cerebral function regulator), Tussionex(TM) (antitussive) and Metadate(TM) / Equasym XL(TM) (attention-deficit/hyperactivity disorder). UCB employs over 8,500 people operating in over 40 countries and achieved in 2004 revenues of 2.1 billion Euros (including net sales, royalties, and fees) and an operating profit before amortization (EBITA) of 389 million Euros (on a pro forma IFRS basis including 12 months of Celltech and excluding the Surface Specialties activities, divested in February 2005). UCB is listed on Euronext Brussels with a market capitalization of approximately 5.8 billion Euros. About Neogen: Neogen Corporation develops and markets products and services dedicated to food and animal safety. The company's Food Safety Division markets dehydrated culture media, and diagnostic test kits to detect foodborne bacteria, natural toxins, genetic modifications, food allergens, unique proteins, drug residues, plant diseases and sanitation concerns. Neogen's Animal Safety Division markets a complete line of diagnostics, veterinary instruments, veterinary pharmaceuticals, nutritional supplements, disinfectants, and rodenticides. Certain portions of this news release that do not relate to historical financial information constitute forward-looking statements. These forward- looking statements are subject to certain risks and uncertainties. Actual future results and trends may differ materially from historical results or those expected depending on a variety of factors listed in Management's Discussion and Analysis of Financial Condition and Results of Operations in the Company's most recently filed Form 10-K. NOTE: Neogen will conduct a conference call at 2 p.m. Eastern time today, July 6, to discuss the details. To participate in this conference call, contact Investor Relations Manager Terry Maynard at 800-234-5333 or 517-372-9200. Source: Neogen Corporation biz.yahoo.com

To: richardred who wrote (792)	7/7/2005 9:56:15 AM
From: richardred	Respond to of 7265

Millipore to Acquire NovAseptic AB: Broaden Offering to Biotech and Pharmaceutical Companies Thursday July 7, 8:39 am ET Acquisition will expand Millipore's capabilities in aseptic processing and process monitoring tools BILLERICA, Mass.--(BUSINESS WIRE)--July 7, 2005-- Millipore Corporation (NYSE:MIL - News) today announced that it has entered into an agreement to acquire NovAseptic AB. The all cash transaction will result in Millipore acquiring all of the shares of NovAseptic AB for approximately SEK 720 million ($91 million at current exchange rates). NovAseptic, based in Gothenburg, Sweden, provides a range of innovative solutions for aseptic processing applications in biotech and pharmaceutical manufacturing operations. NovAseptic's products include a unique disposable sampling system (NovaSeptum®) and a range of high-performance mixers, valves, and connectors. Martin Madaus, Millipore's Chairman, CEO and President, noted: "NovAseptic's products and customer relationships are a strong strategic fit with Millipore's Bioprocess Division. The talented scientists and engineers at NovAseptic also enhance our already strong applications expertise in the area of aseptic processing. As part of our overall growth strategy, the acquisition of NovAseptic accelerates our plan to expand the breadth of our solutions to biotech and pharmaceutical customers, particularly in the areas of high-performance components and process monitoring tools." The patented NovaSeptum disposable sampling system is used by biotech and pharmaceutical companies to take fluid samples from their drug manufacturing processes. The fully-closed system eliminates the risk of false positives due to biological contaminants, and greatly improves operator productivity and safety. NovaSeptum has been adopted by a number of pharmaceutical and biotechnology companies, and several new evaluations are in progress. NovAseptic's other aseptic processing components include high-performance mixers and valves, optimally designed for performance and reliability in stringent drug production environments. These components enjoy an exceptional quality reputation with customers. Johan Westman, Managing Director of NovAseptic, commented: "NovAseptic AB has been looking for a strong partner to more rapidly expand its offering to a broader range of customers worldwide, and Millipore is a perfect match. We are both active in process sampling and monitoring, and in critical bioprocessing components; the product lines are complementary; and, most importantly, we share a vision of the industry's future and the role we can play in that future." Terms of the agreement call for Millipore to purchase over 90 percent of the shares of NovAseptic AB from founders and other majority owners. Millipore expects the balance of shares to be purchased on similar terms from the remaining shareholders. The transaction is expected to close, subject to regulatory approval and customary closing conditions, within the next 45 days. NovAseptic has achieved a compound annual growth rate of 20 percent over the past three years and is expected to generate sales of approximately $35 million in the twelve months following the closing of the transaction. Excluding the impact of acquisition-related charges, integration costs, and amortization of intangibles, Millipore expects the transaction to be slightly accretive to earnings per share in 2005 and accretive by at least $0.05 in 2006. The Company has not yet determined the allocation of the purchase price, and therefore, accurate GAAP earnings projections are not available at this time. About Millipore Millipore is a leading bioprocess and bioscience products and services company, organized into two divisions. The Bioprocess division offers solutions that optimize development and manufacturing of biologics. The Bioscience division provides high performance products and application insights that improve laboratory productivity. Millipore has a deep understanding of its customers' research and manufacturing process needs, and offers reliable and innovative tools, technologies and services. The Company employs approximately 4,500 people worldwide and posted revenues of $883 million in 2004. For additional information on Millipore Corporation, please visit its website at: www.millipore.com Forward Looking Statements: The matters discussed herein, as well as in future oral and written statements by management of Millipore Corporation that are forward-looking statements, are based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements. Potential risks and uncertainties that could affect Millipore's future operating results include, without limitation, foreign exchange rates; regulatory delay in the approval of new therapeutics and their ultimate commercial success; further consolidation of drug manufacturers; competitive factors such as new membrane technology; lack of availability of raw materials or component products on a timely basis; inventory risks due to shifts in market demand; change in product mix; conditions in the economy in general and in the bioscience and bioprocess markets in particular; potential environmental liabilities; the inability to utilize technology in current or planned products due to overriding rights by third parties; difficulties inherent in research and development activities; and the risk factors listed from time to time in Millipore's filings with the SEC. NovaSeptum is a registered trademark of NovAseptic AB Contact: Millipore Corporation Investor Contact: Geoffrey Helliwell, 978-715-1041 or 800-225-3384 Geoffrey_Helliwell@Millipore.com or Media Contact: Thomas Anderson, 978-715-1043 or 800-225-3384 Thomas_Anderson@Millipore.com Source: Millipore Corporation biz.yahoo.com

To: richardred who wrote (792)	4/25/2006 10:27:01 AM
From: richardred	Respond to of 7265

Wall street likes this deal. Millipore stock is up $6.00+. Serologicals sold to Massachusetts company Tuesday April 25, 10:06 am ET Millipore Corp. plans to buy Serologicals Corp. for $1.4 billion in an all cash transaction. Serologicals (NASDAQ: SERO - News) shareholders will receive $31.55 in cash for each share of Serologicals common stock they own. The deal is expected to close by June 30. "We are pleased with the company we built at Serologicals and are proud of our track record of achieving revenue growth, increasing profitability, and delivering value to our customers," said David A. Dodd, president and CEO of Serologicals. "We believe that our combination with Millipore represents an excellent opportunity to achieve attractive long-term growth, enhance product development, and develop a closer partnership with all of our customers in the life sciences and biopharmaceutical markets." Dodd will leave Atlanta-based Serologicals once the merger is complete. Serologicals, which makes biological products and technologies for the research, development, and manufacture of life science products, reported its profit dropped nearly 85 percent to $2.7 million on $274.9 million in revenue in 2005, cut by impairment charges, exit costs and inventory write-offs. Billerica, Mass-based Millipore (NYSE: MIL - News) said it will boost sales of Serologicals' products in international markets such as Europe, Asia and Japan. Millipore's Bioprocess Division will gain a cell culture supplements offering and will enter the $1 billion upstream bioprocessing market. Millipore, a bioprocess and bioscience products and services company, said the combined organization will have about 5,800 employees, will have significantly expanded research and development capabilities and will have a worldwide sales and service organization of about 1,200 professionals. Published April 25, 2006 by the Atlanta Business Chronicle biz.yahoo.com